Articles related to ENDOCRINE THERAPY

Researchers identified a metabolic pathway in which amino acid breakdown generates propionyl-CoA, sustaining cholesterol production and androgen signaling in prostate cancer models. The findings suggest a potential mechanism of hormone therapy resistance, though clinical relevance remains unproven.

Daily low-dose endoxifen reduced mammographic breast density versus placebo in premenopausal women, with fewer tolerability concerns at 1 mg. Whether this surrogate response translates into lower breast cancer incidence remains unknown.

Use of estrogen-only hormone therapy in women over age 70 was associated with lower rates of dementia diagnoses and reduced Alzheimer-related pathology across large observational cohorts. The findings identify an association but do not establish a preventive effect against dementia.

Disease recurrence in HR+/HER2– early BC (EBC) can occur over decades; however, the hazard of recurrence is highest during the first 2 years of adjuvant endocrine therapy, a period associated with endocrine resistance and early metastatic progression.

The combination of imlunestrant plus abemaciclib demonstrated significant progression-free survival benefit across all subgroups, including patients with prior CDK4/6 inhibitor use and those with visceral metastases.

In a cohort of 601 women aged ≥65 years with low-risk breast cancer treated without radiotherapy, the 10-year local recurrence rate was 5.5%, with only 0.5% breast cancer-specific mortality.